Navigation Links
Infinata’s BioPharm Insight Releases Licensing League Tables Report for 4Q12 and YE12
Date:3/4/2013

Norwood, MA (PRWEB) March 04, 2013

Infinata’s BioPharm Insight released its Licensing League Tables Report for 4Q12 and YE12 to subscribers in mid-February. This report provides insight needed to evaluate market opportunities, market values and trends as well as competitive strategies.

The total volume and disclosed value of licensing agreements involving pharmaceutical products picked up in 4Q12. The quarter has seen 110 agreements with an aggregate disclosed value of USD 6,813m. That is an increase of 36% in volume and 42% in value from 3Q12, in which 81 agreements worth USD 4,787m were announced. The Antibody Program agreement between Menarini Group and Oxford BioTherapeutics was the largest deal in 4Q12, potentially valued at USD 1,035m.

Topping the charts in 4Q, legal advisor Wilson, Sonsini Goodrich & Rositi led the volume table having advised on eight transactions valued at USD 551m. While WilmerHale led the global value table for 4Q, having advised on six drug licensing agreements valued at USD 685m.

WilmerHale also led the global and North American volume tables for YE12 with 27 transactions valued at USD 1,283m, while tying with Cooley for the European volume tables, both having advised on eight transactions. Cooley also led the global and North American value tables for YE12 with 26 transactions valued at USD 4,280m and 25 transactions valued at USD 4,272m, respectively. Covington & Burling took the top spot for the European value table for YE12 having advised on seven agreements valued at USD 3,765m.

Access all of BioPharm Insight’s reports by starting a free trial today.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com. Follow BioPharm Insight on LinkedIn and Twitter.

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10476962.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program
2. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
3. Infinata's BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
4. PDL BioPharma to Present at Two Upcoming Investor Conferences
5. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
6. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
7. Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013
8. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
9. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
10. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
11. BioPharm Systems to Host Webinar on an Add-On Solution for Oracle Clinical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2020)... ... May 13, 2020 , ... ... phenotypic readouts, providing little or no information on the drug’s mechanism of action ... characterization of compounds by measuring the activity of molecular pathways. This information can ...
(Date:5/5/2020)... TAMPA, Fla. (PRWEB) , ... May 05, 2020 ... ... technology and solutions company, announced today the launch of its iGlucose® ... The new iGlucose solution utilizes LTE Cat-M1 technology, the industry’s newest and broadest ...
(Date:4/22/2020)... ... April 20, 2020 , ... Global molecular diagnostics ... that Omixon’s founder and chairman Dr. Attila Berces returns as CEO. Outgoing CEO ... since 2014 before stepping into the CEO role in 2017. , In ...
(Date:4/7/2020)... ... 06, 2020 , ... Gateway Genomics , leading developer of direct-to-consumer genetic ... Gender DNA Tests sold in March, just months after attaining the 150,000-test landmark ... where a mom could order her kit online, collect a DNA sample from her ...
Breaking Biology Technology:
(Date:5/21/2020)... ... 21, 2020 , ... Agility Orthopedics, home to dedicated specialists ... is pleased to announce a partnership with Dallas-based Simple Interact to further enhance ... area, Agility Orthopedics is focused on speeding up patient workflows to enhance patient ...
(Date:5/14/2020)... ... May 12, 2020 , ... Akara ... and easily project contracted liabilities with payers, providers and pharmacies – now ... to Commercial and Government entities, Copay and Patient Assistance Program liabilities and ...
(Date:5/14/2020)... ... May 14, 2020 , ... The annual ... representatives, found the 2019 average medical sales rep total compensation increased by $12,000 ... uncertainties amid the COVID-19 global crisis. , The MedReps 2020 Salary Survey revealed ...
Breaking Biology News(10 mins):